1. Kai Zhou; Hua Chen; Xiaoyu Wang; Yanmei Xu; Yufeng Liao; Yuanyuan Qin; Xuewan Ge; Tingting Zhang; Zhonglin Fang; Beibei Fu; Qingzhong Xiao; Fengqin Zhu; Sirui Chen; Xuesheng Liu; Qichao Luo; Shan Gao; Targeted pharmacokinetics and bioinformatics screening strategy reveals JAK2 as the main target for Xin-Ji-Er-Kang in treatment of MIR injury, Biomedicine & Pharmacotherapy, 2022.
2. Lijun Sun; Xiaoyu Wang; Jie Xia; Yanmei Xu; Yufeng Liao; Yuanyuan Qin; Xuewan Ge; Peiwen Zhao; Tong Xu; Xiaoling Zhu; Shan Gao; Rui Xiao; Xuesheng Liu; Kai Zhou; Xin-Ji-Er-Kang protects heart from ischemia-reperfusion injury by rebalancing lipid metabolism, Frontiers in Pharmacology, 2022.
3. Kai Zhou; Jingwei Zhang; Qizhi Wang; Wenyue Liu; Jiali Liu; Lan Yao; Mingmin Cai; Suiying Ni; Qingyun Cai; Guangji Wang; Fang Zhou; Apatinib, a selective VEGFR2 inhibitor, improves the delivery of chemotherapeutic agents to tumors by normalizing tumor vessels in LoVo colon cancer xenograft mice, Acta Pharmacologica Sinica, 2019.
4. Xinxin Ling; Hua Chen; Beibei Fu; Chengshao Ruan; Ming Pana; Kai Zhou; Zhirui Fang; Juntang Shao; Fengqin Zhu; Shan Gao; Xin-Ji-Er-Kang protects myocardial and renal injury in hypertensive heart failure in mice., Phytomedicine, 2021.
